<SEC-DOCUMENT>0000950170-23-053645.txt : 20231017
<SEC-HEADER>0000950170-23-053645.hdr.sgml : 20231017
<ACCEPTANCE-DATETIME>20231017070616
ACCESSION NUMBER:		0000950170-23-053645
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231016
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231017
DATE AS OF CHANGE:		20231017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nkarta, Inc.
		CENTRAL INDEX KEY:			0001787400
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474515206
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39370
		FILM NUMBER:		231328443

	BUSINESS ADDRESS:	
		STREET 1:		1150 VETERANS BOULEVARD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(925) 407-1049

	MAIL ADDRESS:	
		STREET 1:		1150 VETERANS BOULEVARD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nktx-20231016.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-10-17T01:18:35.5539+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:nktx="http://nkartatx.com/20231016" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_52d92b02-3146-4677-a2ba-e2d322866503" name="dei:AmendmentFlag" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024">false</ix:nonNumeric><ix:nonNumeric id="F_61007fb0-dd0d-4e05-92af-987f4b224b8b" name="dei:EntityCentralIndexKey" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024">0001787400</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nktx-20231016.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_17969753-507b-47ec-8ace-cd8f5acd6024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787400</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-16</xbrli:startDate><xbrli:endDate>2023-10-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_8cbd5b58-0291-4e42-bd16-e1e9412acb92" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_5dcfa351-741e-4067-b252-a3c62dd78a2c" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">October 16, 2023</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_a96f0e10-e61f-4713-af33-8f668181e33f" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:'Times New Roman',serif;min-width:fit-content;">Nkarta, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.34%;"></td>
    <td style="width:33.34%;"></td>
    <td style="width:33.32%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_431d932c-b072-4237-8e50-637491156fc1" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_b597cfc5-2e67-44be-8570-f6608eb451fc" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">001-39370</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_7ec29e4f-5f4c-43e1-a358-e57a1554d73f" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">47-4515206</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">(IRS Employer</span></p><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_fd685474-94e1-4337-b572-ba3986357e7f" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">1150 Veterans Boulevard</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_0654e83e-b5d3-41c0-885c-3c8cf081f114" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_a52ff2c8-4503-443a-aea5-cb2a2f092e62" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:4pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_7dfc1617-4e7a-42ad-8042-02c5e1d6a7c1" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">94080</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:4pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code: (</span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_9c16a34b-0536-4f36-800e-cbaa2909c41e" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">925</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_f0081c3c-4bb8-4c7b-b13e-33b4ff9fcd83" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">407-1049</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Not Applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:96%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_60335d6c-ee11-4f32-839e-f87826e94b09" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_18bd9551-a99a-4d2f-8d6b-b1a2c7e04c0f" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_60f62509-d78d-4b4a-b845-1a153bca3758" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_f2bfd777-d584-414f-8977-23a0881015cc" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39%;"></td>
    <td style="width:1%;"></td>
    <td style="width:20%;"></td>
    <td style="width:1%;"></td>
    <td style="width:39%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_a6437604-20cb-48d4-b11f-0124d45aab5c" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_74bcbd5e-c58d-437c-b3f0-5bc6a8767f21" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">NKTX</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_29594cf3-af43-4d9a-9b70-bdb17ea81890" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x2009;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x2009;240.12b-2 of this chapter).</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:9pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_84d4c492-365f-4837-8c5f-e6b4a9139fd1" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_0dcb4d75-b108-4187-a230-7f7629eeb166" contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">On October 17, 2023, Nkarta, Inc. (the &#x201c;Company&#x201d;) announced that, based upon preliminary estimates and information available to the Company, it expects to report that it had cash, cash equivalents, restricted cash and investments of approximately $278.4 million as of September 30, 2023. A copy of the Company&#x2019;s press release is attached hereto as Exhibit 99.1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The preliminary financial information presented above is not a comprehensive statement of the Company&#x2019;s financial position, and is subject to change following the completion of the Company&#x2019;s financial closing procedures. Complete results will be included in the Company&#x2019;s Quarterly Report on Form 10-Q for the three months ended September 30, 2023.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Item 2.05 Costs Associated with Exit or Disposal Activities.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">On October 16, 2023, the Company committed to a reduction in force (the &#x201c;Reduction&#x201d;) that is expected to result in a reduction of 18 positions, representing approximately 10% of the Company&#x2019;s workforce. The Company undertook the Reduction to decrease its costs and create a more streamlined organization to support its operations through multiple clinical data updates expected in 2024. The Reduction, together with other cost containment measures, is expected to extend the Company&#x2019;s cash runway by one year into 2026.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">In connection with the implementation of the Reduction, the Company currently estimates it will incur approximately $1 million to $1.5 million in costs, consisting primarily of cash severance costs and transition support services for impacted employees, which the Company expects to recognize in the fourth quarter of 2023. The Company expects to substantially complete the Reduction by the end of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The estimates of costs and expenses that the Company expects to incur in connection with the Reduction are subject to a number of assumptions and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Reduction.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Item. 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">On October 17, 2023, the Company issued a press release announcing clearance of an Investigational New Drug (&#x201c;IND&#x201d;) application by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) to evaluate NKX019 for the treatment of lupus nephritis (&#x201c;LN&#x201d;) and other corporate updates, which is discussed in more detail in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Also on October 17, 2023 and as previously disclosed, the Company hosted a conference call to discuss its clinical programs and other corporate updates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The information in Items 2.02 and 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), unless the Company specifically states that the information is to be considered &#x201c;filed&#x201d; under the Exchange Act or incorporates it by reference into a filing under the Securities Act or the Exchange Act.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Item. 8.01 Other Events.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">On October 17, 2023, the Company announced the clearance of an IND application by the FDA to evaluate NKX019 for the treatment of LN. The multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory LN. Patients will receive a three-dose cycle of NKX019 at 1 billion or 1.5 billion cells per dose on Days 0, 7 and 14 following lymphodepletion (&#x201c;LD&#x201d;) with single agent cyclophosphamide, an agent with an established safety profile in systemic lupus erythematosus and LN. The study is designed to enroll up to 12 patients, with the first patient expected to be enrolled in the first half of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">In addition to the foregoing study, the Company also announced the opening of a new cohort in its Phase 1 study of NKX019 in relapsed or refractory (&#x201c;r/r&#x201d;) non-Hodgkin lymphoma (&#x201c;NHL&#x201d;). The new cohort introduces a compressed dosing schedule, where patients will receive NKX019 doses on Days 0, 3 and 7 following standard LD with fludarabine and cyclophosphamide, rather than Days 0, 7 and 14 following LD for previous cohorts. This schedule is designed to intensify exposure to NKX019 in the first week after LD, when internal data suggest that NKX019 exposure is highest. The new cohort will target patients (n=6) with large B-cell</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">lymphoma, including those who have received prior CD19-directed CAR-T cell therapy. The Company has decided to no longer enroll new patients into its three previously announced expansion cohorts for NKX019.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The Company also expects to announce clinical updates from its three pipeline programs in 2024: NKX101 (acute myeloid leukemia) in the first half of 2024, NKX019 (NHL) in mid-2024 and NKX019 (LN) in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Forward-Looking Statements</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">This Current Report on Form 8-K contains statements regarding matters that are not historical facts are &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as  &#x201c;anticipates,&#x201d;  &#x201c;believes,&#x201d; &#x201c;expects,&#x201d;  &#x201c;intends,&#x201d; &#x201c;plans,&#x201d; &#x201c;potential,&#x201d;  &#x201c;projects,&#x201d; &#x201c;would,&#x201d; and  &#x201c;future&#x201d; or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, the Company&#x2019;s estimated cash position as of September 30, 2023; the Company&#x2019;s expected cash runway; anticipated costs associated with the Reduction, including specific categories of costs and future cash expenditures and the timing of when such costs are expected to be recognized; the Company&#x2019;s position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX101 and NKX019; the therapeutic potential, accessibility, tolerability and safety profile of NK cell therapies, including NKX019 for the treatment of autoimmune disease, such as lupus nephritis; and plans and timelines for the future availability and presentation of NKX101 and NKX019 clinical data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.08%;"></td>
    <td style="width:2.02%;"></td>
    <td style="width:90.9%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nktx-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Press Release issued on October 17, 2023.</span></a></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Nkarta, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Date: October 17, 2023</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">/s/ Alicia Hager</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Alicia J. Hager, J.D., Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Chief Legal Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nktx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><img src="img220989892_0.jpg" alt="img220989892_0.jpg" style="width:254px;height:65px;">&#160;</p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Estimated cash and cash equivalents of $278.4 million as of September 30, 2023</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:14pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Conference call scheduled for today, October 17, 8:00 am ET</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, for the treatment of lupus nephritis.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We believe that NKX019, as an NK cell-based approach, has the potential to distinguish itself in the growing field of cell therapy for autoimmune diseases through improved access and tolerability. Off-the-shelf availability reduces patient burden and eliminates the need for costly infrastructure and treatment delays required for autologous cell therapies. Our proprietary engineering may also improve safety through a reduced need for lymphodepletion. NKX019 is active immediately and is self-sustaining, without the need for large cytokine surges from preparative chemotherapy,&#x201d; noted David R. Shook, M.D., Chief Medical Officer of Nkarta. &#x201c;Patients with severe autoimmune diseases such as lupus nephritis need safe and novel therapies. We will continue to work closely with leading investigators to bring the promise of</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">cell therapy to patients in need to explore this potentially transformative therapeutic approach.&#x201d;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by abnormal B cell function and autoantibody production and results in a range of clinical manifestations including organ damage and an increased risk of death. Lupus nephritis (LN) is among the most severe manifestations of SLE. Approximately 40 percent of the estimated 200,000 patients in the U.S. diagnosed with SLE will develop LN. Up to 30 percent of patients with LN progress to end stage kidney disease, which can be fatal unless dialysis or a kidney transplant is received.(1)</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory LN. Patients will receive a three-dose cycle of NKX019 at 1 billion or 1.5 billion cells per dose on Days 0, 7 and 14 following lymphodepletion (LD) with single agent cyclophosphamide (cy), an agent with an established safety profile in SLE and LN. The study is designed to enroll up to 12 patients, with the first patient expected to be enrolled in the first half of 2024.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;The potential of cell therapy to reset the immune system and provide long-term, drug-free remissions for patients with severe autoimmune disease may represent the biggest medical breakthrough in the last 50 years of rheumatology,&#x201d; said Roberto Caricchio, M.D., the </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Myles J. McDonough Chair in Rheumatology, </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Professor of Medicine, and Chief of the Division of Rheumatology in the Department of Medicine at the University of Massachusetts Chan Medical School. &#x201c;Patients with lupus nephritis have limited treatment options, and the early results with cell therapy suggest that we may be defining a new era of treatment.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Corporate Updates</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nkarta also announced cost containment measures designed to extend its projected cash runway by one year into 2026, funding its operations well beyond the multiple clinical data updates expected in 2024. Nkarta estimates that, as of September 30, 2023, it had cash, cash equivalents, restricted cash, and investments of $278.4 million. This figure is preliminary and subject to completion of Nkarta&#x2019;s financial closing procedures. The decrease in forecasted spend includes a reduction in and re-allocation of headcount combined with a stringent cap on future headcount growth, planned centralization of operations to a single location and early success in the optimization of Nkarta&#x2019;s manufacturing platform.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The company expects to announce clinical updates from its three pipeline programs in 2024: NKX101 (AML) in the first half of 2024, NKX019 (NHL) in mid-2024 and NKX019 (AID) in 2024. Nkarta will evaluate options to advance each program with additional investment on the basis of those data readouts.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;The clearance of Nkarta&#x2019;s IND for NKX019 in lupus nephritis is an important achievement for Nkarta, and we feel NK cell therapy is ideally suited for the treatment of autoimmune disease,&#x201d; said Paul J. Hastings, President and CEO of Nkarta. &#x201c;Nkarta is well-capitalized with runway that extends into 2026 and beyond key data readouts across the three programs. We plan to remain disciplined about our expenditures as we focus on execution and the multiple opportunities for near- and long-term value creation.&#x201d;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We&#x2019;ve taken the unfortunate but necessary step to streamline our workforce and reconfigure our R&amp;D approach to be in the best position to advance our multiple cell therapies programs,&#x201d; Hastings continued. &#x201c;We are grateful to the talented and committed members of our team who will be departing Nkarta. I thank each of them personally for their dedication to Nkarta and our mission to bring accessible and life-changing cell therapies to patients in need.&#x201d;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Clinical Program Updates for NKX101 in AML</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In June 2023, Nkarta reported updated Phase 1 clinical trial results for NKX101, its allogeneic, off-the-shelf CAR NK cell therapy candidate engineered to target NKG2D ligands, which are overexpressed on cancer cells. In the cohort of patients with relapsed or refractory (r/r) AML who received treatment cycles with a three-dose regimen of NKX101 at 1.5 billion cells per dose after LD with fludarabine (flu) and cytarabine (Ara-C), four of six patients achieved complete response (CR/CRi); three responses were MRD negative.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nkarta continues to expect enrollment of 12 to 20 additional patients in the cohort using flu/Ara-C for LD, and enrollment is ongoing. A clinical update that includes preliminary safety and response data from these additional patients is expected in the first half of 2024. Nkarta also plans to present an update at a medical meeting in late 2023 that includes follow-up data on the six patients from the June 2023 report.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As previously discussed, the NKX101 clinical protocol was amended to enable retreatment and consolidation. As part of ongoing scale-up and optimization of manufacturing across its platform, Nkarta also successfully filed a manufacturing process change amendment with the FDA. The focus of the process change was to enhance product yield to meet anticipated clinical demand and prepare for potential commercial scale manufacturing. After pausing for inventory build up, patient enrollment resumed with material generated with the optimized manufacturing process.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Clinical Program Update for NKX019 in NHL</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nkarta announced today the opening of a new cohort in its Phase 1 study of NKX019 in r/r NHL. The new cohort introduces a compressed dosing schedule, where patients receive NKX019 doses on Days 0, 3 and 7 following standard LD with flu and cy. In previous cohorts, NKX019 has been administered on Days 0, 7 and 14 following LD. This schedule is designed to intensify exposure to NKX019 in the first week after LD, when internal data suggest that NKX019</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">exposure is highest.  The new cohort will target patients (n=6) with large B-cell lymphoma (LBCL), including those who have received prior CD19-directed CAR-T cell therapy. Nkarta may also use data from this cohort to inform future dosing strategies across its platform.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In December 2022, Nkarta announced the opening of three dose expansion cohorts to evaluate NKX019 monotherapy and NKX019 in combination with rituximab in patients with LBCL. Preliminary results from these cohorts did not meet Nkarta&#x2019;s expectations, based on the clinical experience of NKX019 in the dose finding portion of the Phase 1 study. As a result, Nkarta is no longer enrolling patients in these dose expansion cohorts. Preliminary data from the dose compression cohort are expected mid-2024.Nkarta plans to evaluate the results from this cohort before committing additional resources to the NHL program.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Calibri;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">CDC Fact Sheet for Lupus: </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">https://www.cdc.gov/chronicdisease/resources/publications/factsheets/lupus.htm</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">; Parikh 2020, Am J Kidney Dis. 76(2):265-281; Pryor 2021, Rheum Dis Clin North Am. 47(1): 41&#x2013;53; Mahajan 2020, Lupus, 29(9): 1011-1020.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Conference Call Information</font><font style="color:#165164;white-space:pre-wrap;font-weight:normal;font-size:14.5pt;font-family:'Arial',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nkarta management will discuss its program in autoimmune disease and other corporate updates on Tuesday, October 17, at 8:00 a.m. ET. To access the live webcast, please register online on the </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investors section</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> of Nkarta&#x2019;s website. An archived webcast will be available on the Company&#x2019;s website approximately two hours after the event.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About NKX019</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About NKX101</font><font style="color:#165164;white-space:pre-wrap;font-weight:normal;font-size:14.5pt;font-family:'Arial',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors. It is engineered with a chimeric antigen receptor (CAR) targeting NKG2D ligands on tumor cells. NKG2D, a key activating receptor found on naturally occurring NK cells, induces a cell-killing immune response through the detection of stress ligands that are widely expressed on cancer cells. NKX101 is also engineered with a membrane-bound form of interleukin-15 (IL15) for greater persistence and activity without exogenous cytokine support.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Nkarta</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company&#x2019;s website at </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.nkartatx.com</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cautionary Note on Forward-Looking Statements</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Statements contained in this press release regarding matters that are not historical facts are &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as  &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d;  &#x201c;expects,&#x201d;  &#x201c;intends,&#x201d; &#x201c;plans,&#x201d; &#x201c;potential,&#x201d;  &#x201c;projects,&#x201d; &#x201c;would,&#x201d; and  &#x201c;future&#x201d; or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, statements concerning Nkarta&#x2019;s expectations regarding any or all of the following: Nkarta&#x2019;s position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX101 and NKX019; the therapeutic potential, accessibility, tolerability and safety profile of NK cell therapies, including NKX101 for the treatment of cancer and NKX019 for the treatment of autoimmune disease, such as lupus nephritis, and cancer; the potential advantages of CAR NK cell therapies and NKX019, in particular, over other cell therapies for the treatment of autoimmune disease; plans and timelines for the future availability and presentation of NKX101 and NKX019 clinical data; Nkarta&#x2019;s plans to reduce future spend; and Nkarta&#x2019;s estimated cash position and expected cash runway.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Nkarta&#x2019;s limited operating history and historical losses; Nkarta&#x2019;s lack of any products approved for sale and its ability to achieve profitability; the risk that the results of preclinical studies and early-stage clinical trials may not be predictive of future results; Nkarta&#x2019;s ability to raise additional funding to complete the development and any commercialization of its product candidates; Nkarta&#x2019;s dependence on the clinical success of its two lead product candidates, NKX101 and NKX019; that Nkarta may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Nkarta&#x2019;s ability to obtain, maintain and protect its intellectual property; Nkarta&#x2019;s dependence on third parties in connection with manufacturing, clinical trials and pre-clinical studies; the complexity of the manufacturing process for CAR NK cell therapies; the availability of components and supplies necessary for the conduct of our clinical trials; and Nkarta&#x2019;s ability to implement cost reduction measures as planned.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">These and other risks and uncertainties are described more fully in Nkarta&#x2019;s filings with the Securities and Exchange Commission (&#x201c;SEC&#x201d;), including the &#x201c;Risk Factors&#x201d; section of Nkarta&#x2019;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the SEC on August 10, 2023, and Nkarta&#x2019;s other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Nkarta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nkarta Media/Investor Contact:</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Greg Mann</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nkarta, Inc.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">gmann@nkartatx.com</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img220989892_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img220989892_0.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   E"@
M P $     0   )@     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ "7_V@ , P$
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M1110 5_,[_P<KW=W:?"+X5FTEEB+>*=4!,3LA/\ H2]=I%?TQ5_,K_P<O_\
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M97_@Y?\ ^20_"K_L:=5_](5K^FJOYE?^#E__ ))#\*O^QIU7_P!(5KZO@?\
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M>&O%'AKQGHT7B+PCJ%EJFGS[O(OM.GCN;>38Q5MDL19&PP(.#P016[7Y-_\
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M\5?AC\1?A1\,;7P!XBT+7);7Q-J<ES'I%_;WCQ(UDH5G$+N5!/ )&,U_)_\
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MX749)O"U6GVEJOO5FON9]%E7B_7C)+&45)=XZ/[FVG^!_IX45_/I_P $XO\
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M=/9:EIMZFR6&5.Q'0JPPRLI*LI#*2"#7JWPT_:1\;?#GX'?$+]GR!WN/#GQ
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MC#_P3M\:ZA_P2W'[ WPSUW3[_5K/3].L+36]:1[&VF%IJ4=Z[2+"+ADR@90
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M693_ "R_\"/Q&_X(]_\ !-_XX?L!77CZ;XQ:EX;OQXHCTA=/_P"$?N+B<H;
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MG&:\-C_UB_[PKVLMHRIX:E3GO&*3^22/"S;$1JXNM5AM*4FO1ML__]/]!?\
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MJ***_F@_JX_FH_X.6O\ DA'PQ_['2]_]-TE?Q[5_83_P<M?\D(^&/_8Z7O\
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M3_Y,5U;_ +*'JO\ Z3VE?O=7XKQ:K9GB4OYF?OW!COE6%_PH*_BG_P"#CO\
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M;ON7Z>;;Q?C7BT,TUO*EQ;N\<D;!XY$8JRLO(92.00>A%?6G_!3K7;_XK_\
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M./\ @.:_ISB.LZ> Q$H[J+_(_DGA:C&KF6&A/5.<?S/[H:***_ED_L$****
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M $W25_'M7]%^'W_(JI>LOS9_+_B=_P C>KZ1_P#24?VH_P#!M_\ \F8^+/\
MLI5[_P"FW3Z_H/K^?#_@V_\ ^3,?%G_92KW_ --NGU_0?7XSQC_R,\1ZG[MP
M1_R*<+_A"BBBOFCZH**** "OYE?^#E__ ))#\*O^QIU7_P!(5K^FJOYE?^#E
M_P#Y)#\*O^QIU7_TA6OJ^!_^1KA_5_DSXWQ!_P"1/B?1?^E(_D)K^VK_ (-S
M?^3&M;_[*+J?_I)95_$K7]M7_!N;_P F-:W_ -E%U/\ ])+*OUGQ'_Y%C_Q+
M]3\9\*_^1LO\,OT/WVHHHK^>S^F KY+_ &\]#N/$O[%7Q6T*U0R27/@#7$5
M,DD64K=/PKZTK#\3^'[#Q9X;U#PMJJ[K74[&?3[E>N8KB-HW'XJQK?"UO9U8
M5.S3^XY\70]K2G3_ )DU]Z/\KB-@T:L.X!K]8O\ @B1XZ@\#?\%(O JW;A(M
M:@U70"6. 9+JRE>(?4R1J![XK\S_ (A>"M3^&OC[7/ASK2&.\\/ZQ>:)=(PP
M1+8S/ WYE,_C6Q\'OB9K7P8^+/AGXN^'2?MWAC7K'7;8#JS64Z3;/^!A2I]B
M:_JG,<.L3A:M*/VXM+YK0_CK*L4\)C*5:2^"2;^3U/\ 49HKCOAYXYT#XG>
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M[5_1?A]_R*J7K+\V?R_XG?\ (WJ^D?\ TE']J/\ P;?_ /)F/BS_ +*5>_\
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MO_I/:5^]U?B_%_\ R,\3_B9^^<%_\BK"_P"%!7\4_P#P<=_\GG>%?^R>6_\
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M2$?#'_L=+W_TW25_'M7]%^'W_(JI>LOS9_+_ (G?\C>KZ1_])1_:C_P;?_\
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MEVCB.[,;9&WICFOU+HHKYS'XV>)K3KU-Y.[/JLNP%/"T(8>E\,597"OYP_\
M@K]_P2U_:B_;<_:*T/XH?!+_ (1K^S-/\)1:+<?VSJ#VDWVA+J>8[46"4%=L
MB\Y'.>*_H\HKHR?-ZV!K+$4+7U6OF<N=Y)1S##O#8B_*VGIIL?PS?\0]O_!0
M;_J0_P#P=S?_ "'7]=_[#OP=\8?L^_LC?#[X*_$#[)_;7AKPW;:5J7V"4S6_
MGQ9W>7(50LO/!*CZ5]545Z>><68K,*<:6(M9.^BM^IY7#_!F#RRK*KAKW:MJ
M[^?8****^8/K HHHH *_GQ_X*R?\$<=6_:V\:6?QY_9G.C:9XQN66S\4V.IR
MM:6>IPHN(KSS(XY-MS& $?*8E3!)#)\W]!U%>GE.;5\%65>@[/\ !^3/*SG)
M</CZ#P^)C=/[T^Z/X9O^(>W_ (*#?]2'_P"#N;_Y#K[B_8 _X)F_\%1OV$?C
MM:_$WPP?!%[HEZ8['Q9X?&O3+'J.G[LG;FSVK<0Y+P/C@Y4_*[5_5O17TV+\
M0<=7IRHU8Q<9:-6_X)\E@_#3+\/5C7HRFI1=T^;_ ( U"Q4%A@D<CKBG445\
M,?H04444 5KVRL]2LY=/U"*.>">-HIH)E#QR(XPRLK AE(X((P17XE_M5_\
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KLP:_N4HK[G#>(>84J<:4>6T4DM.VG<_/L7X9996JSK3YKR;;UZMW['__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nktx-20231016_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-10-17T01:18:35.8267+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nktx-20231016_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-10-17T01:18:35.6749+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="nktx-20231016.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nktx-20231016.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-10-17T01:18:35.6945+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://nkartatx.com/20231016" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:nktx="http://nkartatx.com/20231016" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktx-20231016_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktx-20231016_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140534266976976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 16, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 16,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Nkarta, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001787400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4515206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1150 Veterans Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">407-1049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>nktx-20231016_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nktx-20231016.xsd" xlink:type="simple"/>
    <context id="C_17969753-507b-47ec-8ace-cd8f5acd6024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787400</identifier>
        </entity>
        <period>
            <startDate>2023-10-16</startDate>
            <endDate>2023-10-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_52d92b02-3146-4677-a2ba-e2d322866503">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_61007fb0-dd0d-4e05-92af-987f4b224b8b">0001787400</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_8cbd5b58-0291-4e42-bd16-e1e9412acb92">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_5dcfa351-741e-4067-b252-a3c62dd78a2c">2023-10-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_a96f0e10-e61f-4713-af33-8f668181e33f">Nkarta, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_431d932c-b072-4237-8e50-637491156fc1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_b597cfc5-2e67-44be-8570-f6608eb451fc">001-39370</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_7ec29e4f-5f4c-43e1-a358-e57a1554d73f">47-4515206</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_fd685474-94e1-4337-b572-ba3986357e7f">1150 Veterans Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_0654e83e-b5d3-41c0-885c-3c8cf081f114">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_a52ff2c8-4503-443a-aea5-cb2a2f092e62">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_7dfc1617-4e7a-42ad-8042-02c5e1d6a7c1">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_9c16a34b-0536-4f36-800e-cbaa2909c41e">925</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_f0081c3c-4bb8-4c7b-b13e-33b4ff9fcd83">407-1049</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_60335d6c-ee11-4f32-839e-f87826e94b09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_18bd9551-a99a-4d2f-8d6b-b1a2c7e04c0f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_60f62509-d78d-4b4a-b845-1a153bca3758">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_f2bfd777-d584-414f-8977-23a0881015cc">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_a6437604-20cb-48d4-b11f-0124d45aab5c">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_74bcbd5e-c58d-437c-b3f0-5bc6a8767f21">NKTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_29594cf3-af43-4d9a-9b70-bdb17ea81890">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_84d4c492-365f-4837-8c5f-e6b4a9139fd1">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_17969753-507b-47ec-8ace-cd8f5acd6024"
      id="F_0dcb4d75-b108-4187-a230-7f7629eeb166">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,<X45<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #'.%%7.Z)@\^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VEAA=#M1?&D(+B@> N3V=U@TX1DI-VWMZV[740?P&-F_GSS
M#4R#46-(])Q"I,2.\LWHNSYKC%MQ9(X:(..1O,GEE.BGYCXD;WAZI@-$@Q_F
M0%!)N0%/;*QA S.PB"M1M(U%C8D,AW3&6USQ\3-U"\PB4$>>>LZ@2@6BG2?&
MT]@U< 7,,*;D\W>![$I<JG]BEPZ(<W+,;DT-PU .]9*;=E#P]O3XLJQ;N#ZS
MZ9&F7]EI/D7:BLODU_KN?O<@VDI6=:%DH6YW2FFYT4J]SZX__*["/EBW=__8
M^"+8-O#K+MHO4$L#!!0    ( ,<X45>97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( ,<X45>7BKL<P
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( ,<X45<'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ QSA15SNB
M8//M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ QSA15YE<G",0!@  G"<  !,              ( !RP$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #'.%%7V:C&@G($   T
M$0  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ QSA15Y^@&_"Q @  X@P   T              ( !M P
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #'.%%7EXJ[',     3 @  "P
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52P4&      D "0 ^ @  %!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nktx-20231016.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="nktx-20231016.htm">nktx-20231016.htm</File>
    <File>nktx-20231016.xsd</File>
    <File>nktx-20231016_lab.xml</File>
    <File>nktx-20231016_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nktx-20231016.htm": {
   "nsprefix": "nktx",
   "nsuri": "http://nkartatx.com/20231016",
   "dts": {
    "inline": {
     "local": [
      "nktx-20231016.htm"
     ]
    },
    "schema": {
     "local": [
      "nktx-20231016.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nktx-20231016_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktx-20231016_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_17969753-507b-47ec-8ace-cd8f5acd6024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nktx-20231016.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17969753-507b-47ec-8ace-cd8f5acd6024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nktx-20231016.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://nkartatx.com/20231016/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-23-053645-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-053645-xbrl.zip
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MX$LP<I*(.)Z2#S)A22A93"[J(?=@CF&'',0Q.<>W<G(N<I%="=[!+O_P=E0
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M-R7[!M4*%=@>N\+J5:%@5G^3'+]'4F1$34&LY-+#DU\6(;3\\OOZI\7>)P#
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M^]8GI/JM3*0P/&H:\Z/J&TXO?VW'EL[2@AQ,)C'H(K!3;B''/%]B\Y9J/A]
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MR!A)Y;M6/(/$+U%[0599**'69+.FX"NS#)K&3?L$-E*E\8"Z4V;+=H(YLQ&
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MIH9/WNU8.RW"M@=AS6KJ+\G3/Y:<QZ+%:NM!;I'4(JE%4HNDE[)SM:B\-_$
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MSUL8@JQ@W$>($$ "PVPQ?:R.N22H6D$',&1(0T.(_1.H@]5KDHXC5] ?SX#
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MU['E^[(0 VSLO=X!,O5E5IDPS^"S"M.7?@YI.\)LE9=+DZHR4R3R)C$0 >+
M3$,;H*5*->:6.=<$GM""C*NF\DZR$3N'87'U)Y^10TXDJ]I<DT.Z:O!C)>;6
MY)B *B4)6;0/!28W?@%'CI?2$U$8$J3G\D:GXFHBWBZ-N1Z)UY-S'$EG2ZWF
MXC5&1<<+5DPG.#G "^YHFHC D6]ZSNL*G$G4W\(?59,LB4_7A+";"Q&19UZ
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M@3@[K&D_/YB9=/7YGYX?+.L\^_S_ 5!+ 0(4 Q0    ( ,<X45?G#\5/(!T
M !@/ 0 1              "  0    !N:W1X+3(P,C,Q,#$V+FAT;5!+ 0(4
M Q0    ( ,<X45>D4#V=$@,  )T)   1              "  4\=  !N:W1X
M+3(P,C,Q,#$V+GAS9%!+ 0(4 Q0    ( ,<X45>]J:),@@8  %Y(   5
M          "  9 @  !N:W1X+3(P,C,Q,#$V7VQA8BYX;6Q02P$"% ,4
M" #'.%%7&>J8_[T$   ?+0  %0              @ %%)P  ;FMT>"TR,#(S
M,3 Q-E]P<F4N>&UL4$L! A0#%     @ QSA15X7IQSL_&P  1*8   \
M         ( !-2P  &YK='@M97@Y.5\Q+FAT;5!+!08     !0 % $$!  "A
%1P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
